Skip to content

Trial · Interventional

CompletedPhase 2Registry data

Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)

NCTNCT00074529 (opens ClinicalTrials.gov in a new tab)Other id0677-030Other idFormally-BG0812AZOther idMK0677-030Other id2006_412
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase 2
Enrollment
512 participants (actual)
Sponsor
Merck Sharp & Dohme LLC · Industry
Design
Randomized · Double masking
Countries
Not stated
Start
Oct 2003
Primary completion
Jan 2006
Completion
Jan 2006
First posted
16 Dec 2003 (estimated)
Last update posted
24 Jul 2015 (estimated)
Conditions
Alzheimer's Disease

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
20032004200520062007
  1. Ph 2

    Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)

    NCT00074529

    Oct 2003 to Jan 2006

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

An investigational drug (MK0677) will be studied to determine whether it helps the memory and cognition of patients with Alzheimer's Disease.

Interventions

  • MK0677Drug

Arms0

The registry lists no arms for this trial.

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Cognitive function over 12 month period; safety and tolerability

    Time frame · over 12 month period

Secondary outcomes(1)

  1. AD symptoms over a 6 month and 12 month period measured by the CIBIC + and the ADAS-Cog.

    Time frame · over a 6 month and 12 month period

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2008

6 results

Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.

Sevigny et al. 2008Neurologycited by 73

PMID 19015485DOI 10.1212/01.wnl.0000335163.88054.e7PUB-19015485

Full text at the publisher6 results
Publisher pageSee results (6)

Other registry references

References listed at the registry that are not in PepBank. They link to PubMed.

  • DerivedSevigny JJ, Peng Y, Liu L, Lines CR. Item analysis of ADAS-Cog: effect of baseline cognitive impairment in a clinical AD trial. Am J Alzheimers Dis Other Demen. 2010 Mar;25(2):119-24. doi: 10.1177/1533317509350298. PMID 19949163

Eligibility

Who could join, as posted.

Sex
All
Age
from 50 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
* Patients must have probable Alzheimer's disease of mild or moderate severity. * A brain scan and laboratory results must be consistent with Alzheimer's disease. * The patient must be otherwise medically healthy.

PepBank is a research reference. Talk to a doctor before you use any peptide.